Role of EZH2 in epithelial ovarian cancer: from biological insights to therapeutic target

Hua Li and Rugang Zhang*

Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, USA

EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2), which generates a methyl-epigenetic mark at lysine 27 residue of histone H3 (H3K27me3) to silence gene expression. EZH2 target genes are involved in a variety of biological processes such as stem cell pluripotency, cell proliferation, and oncogenic transformation. EZH2 is often over-expressed in epithelial ovarian cancer (EOC) cells and in ovarian cancer-associated stromal endothelial cells. Notably, EZH2 promotes cell proliferation, inhibits apoptosis and enhances angiogenesis in EOCs. In contrast to genetic alterations, which are typically non-reversible, epigenetic alterations are reversible. Thus, inhibiting EZH2/PRC2 activity represents an attractive strategy for developing ovarian cancer therapeutics by targeting both ovarian cancer cells and ovarian tumor microenvironment. Here we discuss the progress recently obtained in understanding how EZH2/PRC2 promotes malignant phenotypes of EOC. In addition, we focus on strategies for targeting EZH2/PRC2 to develop novel EOC epigenetic therapeutics.

Keywords: epithelial ovarian cancer, EZH2, PRC2, EZH2 inhibitors, epigenetic therapeutics

EXPRESSION AND REGULATION OF EZH2/PRC2

EZH2, when presents in PRC2, can add up to three methyl groups to the lysine 27 of histone H3 (H3K27Me3) via its SET domain methyltransferase (Bracken et al., 2006). EZH2 is often over-expressed in human EOC cells compared with normal human ovarian surface epithelial cell (Li et al., 2010). In addition, there is recent evidence to suggest that a proportion of high-grade serous EOC may arise from distal fallopian tube epithelial cells (Levanon et al., 2008; Kurman and Shih, 2010; Kuhn et al., 2012). Notably, compared with normal fallopian tube epithelium, EZH2 is over-expressed in high-grade serous EOC (Li et al., 2012b). Likewise, other components of PRC2 such as SUZ12 are also over-expressed in EOC compared with either normal human ovarian surface epithelial cells or fallopian tube epithelial cells (Li et al., 2012b). Indeed, the expression of EZH2 and SUZ12 positively correlates with each other in human EOCs, further supporting the idea that EZH2 functions within PRC2 in EOC (Li et al., 2012b).

Interestingly, although EZH2 upregulation correlates with an increased level of H3K27Me3 in EOC cell lines (Li et al., 2010), there is evidence to suggest that EZH2 levels do not correlate with H3K27Me3 levels in primary EOC specimens (Wei et al., 2008). There are a number of possible reasons for this phenomenon. First, although the core subunits of PRC2 such as EZH2, SUZ12, and EED are over-expressed in EOC cells (Li et al., 2010, 2012b), the expression of other PRC2 associated proteins such as RbAp48 and AEBP2 can also affect the methyltransferase activity of EZH2 and/or the recruitment of PRC2 to its target genes (Cao and Zhang, 2004). For example, in vitro histone methyltransferase assay showed that addition of RbAp48 to EZH2–EED–SUZ12 complex or AEBP2 to the EZH2–EED–SUZ12–RbAp48 complex significantly increased the methyltransferase activity of PRC2 (Cao and Zhang, 2004). In addition, it was recently found that EZH2 and other components of PRC2 play a key role in regulating proliferation, apoptosis, and invasion of human EOC cells (Li et al., 2010, 2012b; Lu et al., 2010). In addition, EZH2 regulates EOC microenvironment by enhancing angiogenesis (Lu et al., 2010). Significantly, highly specific small molecule inhibitors of EZH2 methyltransferase activity have recently been developed (Knutson et al., 2012; McCabe et al., 2012b; Qi et al., 2012). Here we will discuss latest advances in understanding the biological function and regulation of EZH2/PRC2 in EOC as well as the therapeutic targeting EZH2/PRC2 in this devastating disease.
that polycomb-like (PCL) family proteins such as PHF19 play a critical role in the recruitment of PRC2/EZH2 to its target genes (Ballare et al., 2012). Biochemically, C-terminal end of PHF19 binds to SUZ12 in the context of an intact PRC2 (Ballare et al., 2012). Knockdown of PHF19 did not affect the stability of the PRC2 complex, but the association of PRC2 with the promoters of target genes was substantially reduced and, consequently, vast majority of target genes lost their H3K27Me3 epigenetic mark (Ballare et al., 2012). Likewise, JARID2 is also important for the recruitment of PRC2 to its target genes (Landeira et al., 2010). Together, these findings demonstrated that a stable association of PRC2 at target genes is required for its gene silencing function and PRC2 associated proteins play a key role in regulating the recruitment of PRC2 to its target genes. Another class of regulators of PRC2’s genomic localization is non-coding RNAs such as HOTAIR (Tsai et al., 2010), XIST (Zhao et al., 2008), and intronic RNAs (Guil et al., 2012). They bind directly to PRC2 to regulate its association with target genes. Finally, histone demethylases such as UTx and JMJD3 can decrease the levels of H3K27Me3 (Agger et al., 2007) and loss of function mutations in UTx have been reported in human cancers (Guil et al., 2011; Jankowska et al., 2011). Thus, it will be interesting to examine the correlation between expression of core subunits of PRC2 and expression of PRC2 associated proteins, non-coding RNAs and histone demethylases in EOC.

In addition to over-expression, gain-of-function EZH2 mutations have been reported in hematopoietic malignancies (Ryan et al., 2011; Majer et al., 2012). The most common mutations occur within the SET domain that confers methyltransferase activity. For example, Y641 mutations have been identified in ~20% of germinal-center diffuse large B-cell lymphomas and in ~7% of follicular lymphomas (Bodor et al., 2011). Interestingly, these mutations are always heterozygous and the resulting cells also carries a wild type copy of EZH2 (Morin et al., 2010; Sneeringer et al., 2010). Mechanistically, the mutant EZH2 exhibits little to no activity for H3K27Me0 substrate and a decreased activity for H3K27Me1 substrate, while display significantly increased activity for H3K27Me2 substrate (Sneeringer et al., 2010). Consequently, the wild type EZH2 retained in these cells accounts for the generation of H3K27Me1 and H2K27Me2, which led to a global increase in H3K27Me3 by the mutant EZH2 in these tumor cells. Notably, A677 mutations in the EZH2’s SET domain also occur in human lymphoma albeit at much lower rate compared with Y641, which exhibits an increased enzymatic activity independent of H3K27 methylation status (McCabe et al., 2012a). This led to a global increase in H3K27Me3 levels (McCabe et al., 2012a). Regardless, EZH2 mutation has not been reported in in EOC and there is no evidence of EZH2 mutation in EOC cells to exposure to TNF inflammatory cytokine (Palacios et al., 2010). Kinase p38 alpha phosphorylates T372 residue of EZH2 in response to exposure to exposure to TNF inflammatory cytokine (Palacios et al., 2010). This leads to an enhanced repression of PRC2 target skeletal muscle stem cell marker to promote cell differentiation. Notably, the relevance of these post-translation phosphorylation modifications in EOC remains to be determined.

ROLE OF EZH2/PRC2 IN EOC

Components of PRC2 are often over-expressed in human EOC cells and their expression positively correlates with markers of cell proliferation such as Ki67 (Li et al., 2010, 2012b). Significantly, higher levels of EZH2 (Lu et al., 2010) or SUZ12 (Li et al., 2012b) expression predict shorter overall survival in EOC patients. Indeed, knockdown of EZH2 (Li et al., 2010) or SUZ12 (Li et al., 2012b) suppresses the growth of human EOC cells in vitro and in vivo in both subcutaneous and orthotopic xenograft EOC models in immunocompromised mice. This is due to induction of programmed cell death or apoptosis (Li et al., 2010, 2012b). In addition, knockdown of EZH2 suppresses the invasion of human EOC cells (Li et al., 2010; Lu et al., 2010; Rao et al., 2010), which correlates with a decrease in transforming growth factor-beta 1 (TGF β1) expression and an increase in E-cadherin expression (Rao et al., 2010). These observed phenotypes correlate with a decrease in the levels of H3K27Me3 in these cells (Rao et al., 2010). Together, these findings are consistent with the notion that EZH2/PRC2 promotes EOC by suppressing cell apoptosis (Li et al., 2010, 2012b) and increasing their invasion potential (Li et al., 2010; Rao et al., 2010) by silencing its target genes through H3K27Me3 epigenetic mark.

Notably, EZH2 expression is upregulated in ovarian cancer stem cell-like cells enriched by chemotherapy (Rizzo et al., 2011) and knockdown of EZH2 leads to loss of stem cell-like properties in these cells (Rizzo et al., 2011), such as anchorage-independent growth and tumor growth in xenograft mouse model. Similarly, it has been demonstrated that compared with cisplatin sensitive parental EOC cells, EZH2 expression is upregulated in in vitro derived cisplatin-resistant EOC cells (Hu et al., 2010). Conversely, knockdown of EZH2 re-sensitized drug-resistant ovarian cancer cells to cisplatin (Hu et al., 2010). Together, these reports support the idea that EZH2 may contribute to chemoresistance by regulating stem-like cell population in EOCs.

Interestingly, EZH2 is also over-expressed in EOC-associated endothelial cells due to a direct paracrine VEGF stimulation (Lu et al., 2010) and EZH2 promotes angiogenesis by silencing vaso-hibin1 (VASH1) (Lu et al., 2010). Consistently, EZH2 knockdown...
in the EOC-associated endothelial cells inhibits angiogenesis and reduces EOC growth, which is further enhanced by EZH2 knockdown in EOC cells (Lu et al., 2010). Thus, EZH2 also contributes to malignant behaviors of EOC by altering EOC-associated tumor microenvironment through promoting angiogenesis. Notably, recent anti-angiogenesis clinical trials by targeting VEGF demonstrated potential benefit when added to standard chemotherapy in the first-line treatment of ovarian cancer (Burger et al., 2011; Perren et al., 2011). Together, these observations suggest that EZH2 is a potential target for designing new anti-angiogenesis therapy in EOC.

Genome-wide chromatin immunoprecipitation followed by deep sequencing analysis and gene expression profile reveal that the number of genes upregulated upon EZH2 knockdown is significantly lower than the number of genes whose genomic loci are directly occupied by EZH2/H3K27Me3 (Li et al., 2012a). This is consistent with the observation that histone deacetylase (Van der Vlag and Otte, 1999) and DNA methylation (Nakamura et al., 2008) also regulate the expression of EZH2 target genes. In addition, VASH1, the cellular networks enriched by EZH2 target genes in EOC cells include cell death, growth and proliferation and reproductive system development, and cancer (Li et al., 2012a). These findings further support EZH2’s proliferation-promoting and apoptosis-suppressing function. Notably, Harakiri (HRK), a proapoptotic gene, is subjected to H3K27Me3 mediated gene silencing in EOC cells and HRK plays a key role in regulating apoptosis induced by suppressing H3K27Me3 (Li et al., 2012b). HRK is also subjected to DNA methylation (Nakamura et al., 2008) mediated gene silencing, further suggesting possible cooperation between H3K27Me3 and DNA methylation mediated gene silencing.

**THERAPEUTIC TARGETING EZH2/PRC2 IN EOC**

In contrast to genetic changes that are non-reversible, epigenetic alterations are reversible. This feature makes epigenetic alterations in cancer an ideal target for developing cancer therapeutics (Dawson and Kouzarides, 2012). Significantly, EZH2 is over-expressed in both EOC cells and EOC-associated endothelial cells and its knockdown suppresses EOC growth (Li et al., 2010; Lu et al., 2010). These observed effects correlate with a decrease in levels of H3K27Me3, the enzymatic product of EZH2 methyltransferase (Li et al., 2010; Lu et al., 2010). Together, these findings strongly suggest that EZH2’s methyltransferase activity is a potential target for developing urgently needed EOC therapeutics.

The first reported inhibitor of EZH2’s methyltransferase activity is DZNep, an inhibitor of S-adenosylhomocysteine (SAH) hydrolase (Tan et al., 2007). However, DZNep indirectly inhibits EZH2 activity by causing the degradation of components of PRC2 through increasing the cellular levels of SAH, the inhibitory byproduct of methyltransferase reaction (Tan et al., 2007). In addition, DZNep is non-specific with major effects on a number of other histone methyl marks and, consequently, has been shown to be very toxic (Miranda et al., 2009). In contrast, a number of new specific EZH2 methyltransferase inhibitors have been reported very recently including most notably GSK126 (McCabe et al., 2012b) and EPZ005687 (Knutson et al., 2012) and E1I (Qi et al., 2012). These inhibitors act in a S-adenosylmethionine (SAM) competitive manner with no effects on expression of components of PRC2 or other histone methyl marks. This characteristic of the newly developed inhibitors allows to distinguish the EZH2’s methyltransferase-dependent and -independent function. In a panel of B-cell lymphoma cell lines, EZH2 methyltransferase specific inhibitors are particularly sensitive in cells harboring mutations in Y641 or A677 residue (McCabe et al., 2012b). Interestingly, the cell line with A677 mutation appears to be most sensitive, which correlates with the fact that A677 mutant efficiently catalyzes all three steps of H3K27 methylation while Y641 mutant preferentially enhance the reaction from di- to trimethylation (McCabe et al., 2012a). In addition, it appears that loss-of-function mutation in H3K27Me3 demethylase UTx may also confer sensitivity to EZH2 inhibitors (McCabe et al., 2012b). However, gain-of-function mutation is not sufficient to predict response to EZH2 inhibitors because certain cell lines with EZH2 mutation are not sensitive to EZH2 inhibitors (McCabe et al., 2012b). Significantly, EZH2 inhibitor GSK126 eradicated the growth of xenografted B-cell lymphoma cells with EZH2 mutations (McCabe et al., 2012b). Despite the fact that EZH2 is essential during development and is known to regulate normal tissue stem cell properties, mice tolerated GSK126 very well with no apparent toxicity (McCabe et al., 2012b). Together, these findings suggest that EZH2 inhibitors such as GSK126 are potential novel epigenetic intervention reagents for B-cell lymphoma harboring gain-of-function EZH2 mutations.

EZH2 inhibitors are equally effective in decreasing H3K27Me3 in cancer cell lines with wild type EZH2 compared with those with gain-of-function EZH2 mutations (Knutson et al., 2012; McCabe et al., 2012b). However, cell lines with wild type EZH2 are typically much less sensitive to GSK126 (McCabe et al., 2012b). This observation suggests that methyltransferase-independent function of EZH2 also contributes to the malignant phenotypes observed in EZH2 over-expressing cancer cells. Notably, EZH2 is over-expressed but not mutated in EOC. In addition, inhibition of PRC2 by knockdown EZH2 (Li et al., 2010) or SUZ12 (Li et al., 2012b) is effective in inhibiting the growth of EOC cells with over-expressed components of PRC2. Therefore, it will be critical to evaluate the effectiveness of EZH2 inhibitors in preclinical models for their effects on EOC cell growth as well as EOC-associated angiogenesis. In addition to inhibiting EZH2’s methyltransferase activity, targeting the PRC2 complex formation, or the associated factors that affect PRC2 genome-wide distribution may represent an alternative strategy for targeting PRC2 in EOCs. Further, given the evidence that EZH2 target genes may also subject to other epigenetic silencing mechanisms (Van der Vlag and Otte, 1999; Nakamura et al., 2008), it will be interesting to examine whether there are synergies between EZH2 inhibitors and inhibitors of other epigenetic silencers such as HDAC and DNA methyltransferase inhibitors. Finally, given its potential role in conferring chemotherapy resistance (Knutson et al., 2012; McCabe et al., 2012b; Qi et al., 2012), it will be interesting to determine whether EZH2 inhibitors re-sensitize chemoresistant EOC cells.

**CONCLUSION AND PERSPECTIVE**

In summary, EZH2 and other components of PRC2 are often over-expressed in EOC cells (Li et al., 2010, 2012b) and EOC-associated endothelial cells (Lu et al., 2010). EZH2/PRC2
promotes proliferation, suppresses apoptosis and increases invasion potential of EOC cells (Li et al., 2010), and enhances angiogenesis of EOC-associated endothelial cells (Lu et al., 2010). The expression pattern and functional importance of EZH2/PRC2 establish it as an exciting target for developing new EOC therapeutics. Thus, it will very interesting to test the newly developed EZH2 inhibitors in relevant preclinical in vitro and in vivo models. In addition to H3K27 residue, EZH2 can also methylate other proteins. For example, EZH2 methylates an orphan nuclear receptor RORα (Lee et al., 2012). Further, EZH2/PRC2 may also have methyltransferase-independent function. Indeed, EZH2 is present in both cytoplasm and nuclei and cytoplasmic EZH2 has been shown to regulate actin polymerization and cell signaling (Su et al., 2005). Accordingly, a further understanding the mechanisms by which EZH2/PRC2 promote EOC will provide scientific rationale for developing inhibitors of EZH2/PRC2 as novel EOC therapeutics.

ACKNOWLEDGMENTS
This work was supported by the National Cancer Institute of the National Institutes of Health (R01CA163377 to Rugang Zhang) and, in part, by a DOD ovarian cancer academy award (OC093420 to Rugang Zhang). Support of Core Facilities used in this study was provided by Cancer Center Support Grant (CCSG) CA101815 to The Wistar Institute. We thank Dr. Benjamin G. Butler for critical reading of the manuscript.

REFERENCES
Agger, K., Cloos, P. A., Christensen, J., Pasini, D., Rose, S., Rappslager, J., et al. (2007). UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731–734.
Altmann, D. A., Wang, H. Q., Skele, K. L., De Rienzo, A., Klein-Santo, A. J., Godwin, A. K., et al. (2004). AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian cancer cell growth. Oncogene 23, 5853–5857.
American Cancer Society. (2012). Cancer Facts & Figures 2012. American Cancer Society.
Ballare, C., O’Riain, C., Wrench, D., Mattheisen, J., Pasini, D., Hansen, K. H., and Helin, K. (2006). Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20, 1123–1136.
Burger, R. A., Brady, M. E., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473–2483.
Cao, R., and Zhang, Y. (2004). SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15, 57–67.
Cha, T. L., Zhou, B. P., Xia, W., Wu, Y., Yang, C.-C., Chen, C. T., et al. (2005). Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310, 306–310.
Chen, S., Bohrer, I. R., Rai, A. N., Pan, Y., Gan, L., Zhou, X., et al. (2010). Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol. 12, 1108–1114.
Dawson, M. A., and Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27.
Gul, Y., Guo, G., Huang, X., Hu, X., Tang, A., Gao, S., et al. (2011). Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875–878.
Huang, H., et al. (2011). Incorporation of chronic myelomonocytic leukemia includes genes associated with nuclear reprogramming. Mol. Cell Biol. 31, 6857–6868.
Klee, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 100, 11606–11611.
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., et al. (2012). A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890–896.
Kuhn, E., Kurman, R. J., and Shi, I. M. (2012). Ovarian cancer is an imported disease: fact or fiction? Curr. Opin. Obstet. Gynecol. Rep. 1, 1–9.
Kurman, R. J., and Shi, I. M. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34, 433–443.
Landez, D., Sauer, S., Poot, R., Dvořáková, M., Mazzarella, L., Jorgensen, H. F., et al. (2010). Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators. Nat. Cell Biol. 12, 618–624.
Lee, J. M., Lee, J. S., Kim, H., Kim, K., Park, H., Kim, J. Y., et al. (2012). EZH2 generates a methyl group dehydrogenase that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol. Cell 48, 572–586.
Levanon, K., Crum, C., and Drapkin, R. (2008). New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26, 5284–5293.
Li, H., Butler, B. G., Vathipadiekal, V., Maradeo, M. E., Stiller, M., Czeasy, C. L., et al. (2012a). ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev. Res. (Phila.) 5, 484–491.
Li, H., Cai, Q., Wu, H., Vathipadiekal, V., Dobbins, Z. C., Li, T., et al. (2012b). SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HHRK. Mol. Cancer Res. 10, 1462–1472.
Li, H., Cai, Q., Godwin, A. K., and Zhang, R. (2010). Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol. Cancer Res. 8, 1610–1618.
Lu, C., Han, H. D., Mangala, L. S., Ali-Fehmi, R., Newton, C. S., Ozburn, L., et al. (2010). Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185–197.
Majer, C. R., Jin, L., Scott, M. P., Knutson, S. K., Kunze, K. W., Heilbeck, H., et al. (2012). A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett. 586, 3448–3451.
McCabe, M. T., Graves, A. P., Ganju, G., Diaz, E., Halsey, W. S., Jiang, Y., et al. (2012a). Mutation of A677 in histone methyltransferase EZH2 in human soft-tissue sarcoma promotes hypermethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. U.S.A. 109, 2989–2994.
McCabe, M. T., Ott, H. M., Ganju, G., Korenchuk, S., Thompson, C., Van Aller, G. S., et al. (2012b). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112.
Miranda, T. B., Cortez, C. C., Yoo, C. B., Liang, G., Abe, M., Kelley, T. K., et al. (2009). DZNep is a global histone methyltransferase inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579–1588.
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, J. A., An, J., Goya, R., et al. (2010). Somatic
mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185.

Nakamura, M., Shimada, K., and Konishi, N. (2008). The role of HRK gene in human cancer. Oncogene 27(Suppl. 1), S105–S113.

Palacios, D., Mozzetta, C., Consalvi, S., Caretto, G., SACcone, V., Proserpio, V., et al. (2010). TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 7, 455–469.

Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496.

Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., et al. (2012). Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. U.S.A. 109, 21360–21365.

Rao, Z. Y., Cai, M. Y., Yang, G. F., He, L. R., MAi, S. J., Hua, W. F., et al. (2010). EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 31, 1576–1583.

Rizzo, S., Hersey, J. M., Mellor, P., Dai, W., Santos-Silva, A., Liber, D., et al. (2011). Ovarian cancer stem cell-like side populations are enriched following chemotherapy and over-express EZH2. Mol. Cancer Ther. 10, 325–335.

Ryan, R. J., Nitta, M., Borger, D., Zukerberg, L. R., Perry, J. A., Harris, N. L., et al. (2011). EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS ONE 6:e28585. doi:10.1371/journal.pone.0028585

Schwartz, Y. B., and Pirrotta, V. (2007). Polycomb silencing mechanisms and the management of genomic programmes. Nat. Rev. Genet. 8, 9–22.

Sneeringer, C. J., Scott, M. P., Kurtz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., et al. (2010). Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. U.S.A. 107, 20980–20985.

Su, I. H., Dobenecker, M. W., Dickson, E., Oser, M., Basavaraj, A., Marqueron, R., et al. (2005). Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121, 425–436.

Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., et al. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050–1063.

Ting, A. H., McGarvey, K. M., and Baylin, S. B. (2006). The cancer epigenome—components and functional correlates. Genes Dev. 20, 3215–3231.

Tsai, M. C., Manor, O., Wan, Y., Mosammaparast, N., Wang, J. K., Lan, E., et al. (2010). Long non-coding RNA as modular scaffold of histone modification complexes. Science 329, 689–693.

Van der Vlag, J., and Otte, A. P. (1999). Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat. Genet. 23, 474–478.

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629.

Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H., Adsary, N. V., et al. (2008). Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 47, 701–706.

Xu, K., Wu, Z. J., Groner, A. C., and He, H. H. (2012). EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 338, 1465–1469.